Apr 30, 2025
Dr. Rany Aburashed, CEO and Founder of Neurogen Biomarking, is using a blood-based biomarker looking at p-tau 217 to detect early signs of Alzheimer's disease, up to 8-10 years before the onset of clinical symptoms. The company has built an ecosystem to provide patients with a comprehensive health assessment with an...
Apr 30, 2025
Dr. Rany Aburashed, CEO and Founder of Neurogen Biomarking, is using a blood-based biomarker looking at p-tau 217 to detect early signs of Alzheimer's disease, up to 8-10 years before the onset of clinical symptoms. The company has built an ecosystem to provide patients with a comprehensive health assessment with an...
Mar 20, 2025
Dr. Sam Clark, Founder and CEO of Terran Biosciences, is developing a long-acting once-daily formulation of a new class of antipsychotic drugs to treat schizophrenia. The use of a prodrug approach to modify the new drug Cobenfy allows for improved bioavailability and has been shown to have fewer side effects...
Mar 20, 2025
Dr. Sam Clark, Founder and CEO of Terran Biosciences, is developing a long-acting once-daily formulation of a new class of antipsychotic drugs to treat schizophrenia. The use of a prodrug approach to modify the new drug Cobenfy allows for improved bioavailability and has been shown to have fewer side effects...
Mar 19, 2025
Joe Tucker, CEO of Enveric Biosciences, is developing non-hallucinogenic psychedelic drugs that aim to induce neuroplasticity and beneficial changes in the brains of patients with mental health disorders. The FDA rejected the approval of MDMA for PTSD treatment due to concerns about the inability to run blind trials to...